Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis

  • days left to enroll
  • participants needed
  • sponsor
    Walter Ageno
Updated on 22 January 2021
venous thromboembolism
deep vein thrombosis
blood clot
venous thrombosis
deep venous thrombosis of lower extremity


The treatment of isolated distal deep vein thrombosis remains one of the most debated issues in the field of venous thromboembolism and only very few studies have directly addressed the issue of treatment in objectively confirmed isolated distal deep vein thrombosis. Aim of this study is to assess the long-term risk of recurrent venous thrombotic events in patients with a first acute symptomatic isolated distal deep vein thrombosis of the leg treated with a standard (12 weeks) or with a shorter (6 weeks) duration of therapy with rivaroxaban.

Condition Venous Thrombosis, Thrombosis, Blood Clots, Deep Vein Thrombosis, deep venous thrombosis of lower extremity, deep venous thrombosis
Treatment Placebo, Rivaroxaban
Clinical Study IdentifierNCT02722447
SponsorWalter Ageno
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Venous Thrombosis?
Do you have any of these conditions: Venous Thrombosis or Thrombosis or Blood Clots or deep venous thrombosis or Deep Vein Thrombosis or deep venous thrombosis of lower extremity?
Objective diagnosis of isolate distal deep vein thrombosis within 72 hours from the evaluation for inclusion in the study and if any type of parenteral treatment was administered at therapeutic doses for 3 days or less (maximum accepted doses of low molecular weight heparin: 6 doses; of fondaparinux: 3 doses)

Exclusion Criteria

Age < 18 years
Any absolute contraindication to anticoagulant treatment
Pregnancy or breast-feeding
Presence of active cancer
Concomitant presence of proximal deep vein thrombosis or pulmonary embolism
Any concomitant indication for long-term anticoagulant treatment
Creatinine clearance 30 ml/min, according to Cockcroft-Gault equation
Cirrhosis Child-Pugh score B or C
Liver disease associated with coagulopathy and high risk of bleeding
Any other contraindication to rivaroxaban as per local SmPC
Failure to provide written informed consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note